Last $21.01 USD
Change Today -0.42 / -1.96%
Volume 61.8K
SRDX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

surmodics inc (SRDX) Snapshot

Open
$21.58
Previous Close
$21.43
Day High
$22.08
Day Low
$20.99
52 Week High
03/7/14 - $25.99
52 Week Low
10/1/14 - $18.00
Market Cap
285.7M
Average Volume 10 Days
55.7K
EPS TTM
$0.91
Shares Outstanding
13.6M
EX-Date
--
P/E TM
23.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for SURMODICS INC (SRDX)

surmodics inc (SRDX) Related Bloomberg News

View More Bloomberg News

surmodics inc (SRDX) Related Businessweek News

No Related Businessweek News Found

surmodics inc (SRDX) Details

SurModics, Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neurovascular, urology, and other markets. The In Vitro Diagnostics segment provides in vitro diagnostic component products and technologies comprising protein stabilization reagents, substrates, polymers and reagent chemicals, antigens, and surface coatings for diagnostic immunoassay and molecular tests, and biomedical research applications. SurModics, Inc. markets its technologies and products worldwide through direct sales force consisting of sales professionals. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

surmodics inc (SRDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.0K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $162.6K
Senior Vice President and General Manager of ...
Total Annual Compensation: $280.0K
Senior Vice President of Legal & Human Resour...
Total Annual Compensation: $280.0K
Vice President of Corporate Development & Str...
Total Annual Compensation: $266.5K
Compensation as of Fiscal Year 2013.

surmodics inc (SRDX) Key Developments

SurModics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014; Provides Earnings Guidance for the Fiscal 2015; Reports Impairment Loss on Investments for the Fourth Quarter Ended September 30, 2014

SurModics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended September 30, 2014. For the quarter, the company’s total revenue was $15,336,000 compared to $14,297,000 for the same period of last year. Operating income from continuing operations was $5,434,000 compared to $5,576,000 for the same period of last year. Income from continuing operations before income taxes was $4,302,000 compared to $5,598,000 for the same period of last year. Income from continuing operations $2,444,000 or $0.18 per basic and diluted share compared to $3,733,000 or $0.26 per basic and diluted share for the same period of last year. Net income was $2,344,000 compared to $3,686,000 for the same period of last year. Net income per basic and diluted share was $0.17 compared to $0.26 for the same period of last year. Non-GAAP operating income from continuing operations was $5,434,000 compared to $5,067,000 for the same period of last year. Non-GAAP income from continuing operations was $3,628,000 compared to $3,439,000 for the same period of last year. Non-GAAP diluted earnings per share from continuing operations were $0.26 compared to $0.24 for the same period of last year. For the year, the company’s total revenue was $57,439,000 compared to $56,132,000 for the same period of last year. Operating income from continuing operations was $18,576,000 compared to $18,820,000 for the same period of last year. Income from continuing operations before income taxes was $18,472,000 compared to $20,360,000 for the same period of last year. Income from continuing operations $12,207,000 or $0.88 per diluted share compared to $14,579,000 or $0.99 per diluted share for the same period of last year. Net income was $12,031,000 compared to $15,167,000 for the same period of last year. Net income per diluted share was $0.87 compared to $1.03 for the same period of last year. Net cash provided by operating activities from continuing operations was $18,539,000 compared to $17,781,000 reported a year ago. Net purchases of property and equipment were $2,278,000 compared to $1,919,000 reported a year ago. Non-GAAP operating income was $19,490,000 compared to $18,129,000 for the same period of last year. Non-GAAP income from continuing operations was $13,262,000 compared to $12,592,000 for the same period of last year. Non-GAAP diluted earnings per share from continuing operations were $0.96 compared to $0.85 for the same period of last year. For fiscal 2015, the company estimates GAAP revenue to be in the range of $57.0 to $60.0 million, essentially flat to up 4% over fiscal 2014. The company anticipates diluted GAAP earnings to be in the range of $0.85 to $0.95 per share. The fiscal 2015 earnings per share guidance includes an increase of approximately 5% to 7% in research and development investment over fiscal 2014 levels primarily related to drug coated balloon activities, similar SG&A expenses to fiscal 2014 levels and a 33.0% to 35.0% income tax rate. The company’s earnings per share and income tax rate guidance exclude the impact of any investment gains or losses. GAAP cash flow from operating activities is expected to range between $16.5 and $18.0 million for fiscal 2015. Capital expenditures for fiscal 2015 are projected to range between $2.2 and $2.5 million. For the quarter, the company’s impairment loss on investments was $1,184,000 compared to $29,000 for the same period of last year.

SurModics, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 04:00 PM

SurModics, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 04:00 PM. Venue: The Westin Grand Central, New York, New York, United States.

SurModics, Inc. to Report Q4, 2014 Results on Nov 06, 2014

SurModics, Inc. announced that they will report Q4, 2014 results at 4:00 PM, Central Standard Time on Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRDX:US $21.01 USD -0.42

SRDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.30 USD -0.01
Biolase Inc $2.57 USD -0.05
Cerus Corp $4.53 USD +0.14
Cutera Inc $10.14 USD -0.04
STAAR Surgical Co $9.21 USD -0.10
View Industry Companies
 

Industry Analysis

SRDX

Industry Average

Valuation SRDX Industry Range
Price/Earnings 24.4x
Price/Sales 5.1x
Price/Book 2.9x
Price/Cash Flow 24.2x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SURMODICS INC, please visit www.surmodics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.